Low Dose Supplemental External Radiation With Pd-103 Versus Pd-103 Alone for Prostate Cancer
| Status: | Completed |
|---|---|
| Conditions: | Prostate Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 40 - 80 |
| Updated: | 4/21/2016 |
| Start Date: | January 2005 |
| End Date: | November 2015 |
Low Dose Supplemental External Radiation With PD-103 Versus PD-103 Alone For Prostate Cancer
The primary purpose of this study is to evaluate two treatment regimens for prostate cancer,
prostate implant with 20 Gy of external beam radiation therapy versus prostate implant with
0 Gy of external beam radiation therapy. Patients diagnosed with intermediate risk prostate
cancer between the ages of 40 and 80 who have chosen brachytherapy with or without external
beam radiation therapy as their intended treatment will be eligible and will be offered
participation.
prostate implant with 20 Gy of external beam radiation therapy versus prostate implant with
0 Gy of external beam radiation therapy. Patients diagnosed with intermediate risk prostate
cancer between the ages of 40 and 80 who have chosen brachytherapy with or without external
beam radiation therapy as their intended treatment will be eligible and will be offered
participation.
Approximately 250,000 men are currently diagnosed with prostatic cancer in the United States
each year. Of those, 70% have stage T1 or T2 disease (apparently limited to the prostate
gland). Clinically localized prostate cancer is a spectrum of disease, ranging from good
prognosis to poor prognosis. Patients with a PSA above 10 ng/ml or Gleason score of 7 to 10
are referred to as intermediate risk, with approximately an 80% chance of cure.
Implantation of radioactive sources directly into the prostate (brachytherapy) delivers a
high, localized radiation dose while sparing most the of the bladder and rectum.
Brachytherapy is well established for other tumor sites, and has become a standard treatment
for prostate cancer.
Establishing that a good quality implant alone is as effective as implant plus beam
radiation will allow us to routinely drop the use of beam radiation, a change in policy that
will decrease the risk of some complications, will be more convenient for patients, and will
lower treatment costs.
each year. Of those, 70% have stage T1 or T2 disease (apparently limited to the prostate
gland). Clinically localized prostate cancer is a spectrum of disease, ranging from good
prognosis to poor prognosis. Patients with a PSA above 10 ng/ml or Gleason score of 7 to 10
are referred to as intermediate risk, with approximately an 80% chance of cure.
Implantation of radioactive sources directly into the prostate (brachytherapy) delivers a
high, localized radiation dose while sparing most the of the bladder and rectum.
Brachytherapy is well established for other tumor sites, and has become a standard treatment
for prostate cancer.
Establishing that a good quality implant alone is as effective as implant plus beam
radiation will allow us to routinely drop the use of beam radiation, a change in policy that
will decrease the risk of some complications, will be more convenient for patients, and will
lower treatment costs.
Inclusion Criteria:
- Patients with previously untreated prostatic cancer.
- Must have PSA 10-20 ng/ml, Gleason 7 to 9
Exclusion Criteria:
- Patients with proven regional lymph node involvement will be excluded.
We found this trial at
2
sites
Click here to add this to my saved trials
Click here to add this to my saved trials